3-[4-(Methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: Synthesis and biological evaluation

Journal of Medicinal Chemistry

Volumn 48, Issue 11, 2005, Pages 3930-3934

  Khanapure, Subhash P ^a   Augustyniak, Michael E ^a   Earl, Richard A ^a   Garvey, David S ^a   Letts, L Gordon ^a   Martino, Allison M ^a   Murty, Madhavi G ^a   Schwalb, David J ^a   Shumway, Matthew J ^a   Trocha, Andrzej M ^a   Young, Delano V ^a   Zemtseva, Irina S ^a   Janero, David R ^a  

^a NitroMed Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (METHYLSULFONYL)PHENYL] 5 (TRIFLUOROMETHYL)(2 PYRIDYL)PHENYLKETONE; ANTIINFLAMMATORY AGENT; BENZOPHENONE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; PROSTAGLANDIN; ROFECOXIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CELL INFILTRATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; INFLAMMATION; LEUKOCYTE; MALE; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT;

ADMINISTRATION, ORAL; ANIMALS; CARRAGEENAN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; INFLAMMATION; MALE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 20144369021     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0582064     Document Type: Article

References (25)

1. For a recent review, see: Khanapure, S. P.; Letts, L. G. Perspectives and clinical significance of the biochemical and molecular pharmacology of eicosanoids. The Eicosanoids; John Wiley & Sons: London, 2004; pp 131-162.
2. Gajaraj, N. M. Cyclooxygenase-2 inhibitors. Anesth. Analg. 2003, 96, 1720-1738.
3. Turini, M. E.; DuBois, R. N. Cyclooxygenase-2: A therapeutic target. Annu. Rev. Med. 2002, 53, 35-57.
4. Vane, J. R.; Botting, R. M. Therapeutic Roles of Selective COX-2 Inhibitors; William Harvey Press: London, 2001; pp 1-548.
5. Rodrigues, C. R.; Veloso, M. P.; Verli, H.; Fraga, C. A.; Miranda, A. L.; Barreiro, E. J. Selective PGHS-2 inhibitors: A rational approach for the treatment of the inflammation. Curr. Med. Chem. 2002, 9, 849-867.
6. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davies, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000, 343, 1520-1528.
7. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, F. W.; Burr, A. M.; Zhao, W. W.; Kent, J. D.; Lefkwith, J. B.; Verburg, K. M.; Geis, G. S. GI toxicity with celecoxib vs NSAIDs for arthritis. JAMA, J. Am. Med. Assoc. 2000, 284, 1247-1255.
8. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
9. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromilish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Quellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, {MK 966, Vioxx, 4-(4′- methylsulfonylphenyl)3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
10. Talley, J. A.; Brown, D. L.; Carter, J. S.; Masferrer, M. J.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
11. Scheen, A. J. Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal antiinflammatory drugs? Rev. Med. Liege 2004, 59, 565-569.
12. Furberg, C. D.; Psaty, B. M.; FitzGerald, G. A. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 2005, 111, 249.
13. Kimmel, S. E.; Berlin, J. A.; Reilly, M.; Jaskowiak, J.; Kishel, L.; Chittams, J.; Strom, B. L. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med. 2005, 142, 157-164.
14. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; Ethier, D.; Falgueyret, J.-P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, J.; Manacini, J.; Quellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girad, Y.; Prasit, P.; Zamboni, R.; Rodger, I. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Chan, C.-C. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
15. Davies, I. W.; Marcoux, J.-F.; Corley, E. G.; Journet, M.; Cai, D.-W.; Palucki, M.; Wu, J.; Larsen, R. D.; Rossen, K.; Pye, P. J.; DiMichele, L.; Dormer, P.; Reider, P. J. A practical synthesis of a COX-2 specific inhibitor. J. Org. Chem. 2000, 65, 8415-8420.
16. Rordorf, C.; Kellett, N.; Mair, S.; Ford, M.; Milosavljev, S.; Branson, J.; Scott, G. Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen; a pilot endoscopic study in healthy male subjects. Aliment. Pharmacol Ther. 2003, 18, 533-541.
17. Berenbaum, F.; Grifka, J.; Brown, J. P.; Zacher, J.; Moore, A.; Krammer, G.; Dutta, D.; Sloan, V. S. Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. J. Int. Med. Res. 2005, 33, 21-41.
18. Khanapure, S. P.; Garvey, D. S.; Young, D. V.; Ezawa, M.; Earl, R. A.; Gaston, R. D.; Fang, X.; Murty, M.; Martino, A.; Shumway, M.; Trocha, M.; Marek, P.; Tam, S. W.; Janero, D. R.; Letts, L. G. Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. J. Med. Chem. 2003, 46, 5484-5504.
19. Julemont, F.; Levai, X.; Michaux, C.; Renard, J.-F.; Winum, J.-Y.; Montero, J.-L.; Damas, J.; Dogne, J.-M.; Pirotte, B. Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J. Med. Chem. 2004, 47, 6749-6759.
20. Khanapure, S. P.; Augustyniak, M. E.; Earl, R. A.; Garvey, D. S.; Gordon, L. G.; Martino, A. M.; Murty, M. G.; Schwalb, D. J.; Shumway, M. J.; Trocha, A. M.; Young, D. V.; Zemtseva, I. S.; Janero, D. R. A potent and highly selective cyclooxygenase-2 (COX-2) inhibitor from a novel, pyridyl metharyl series. Presented at the 228th National Meeting of the American Chemical Sociey, Philadelphia, PA, August 22-26, 2004; Paper MEDI 243.
21. Parker, K. A.; Kallmerten, J. Approaches to anthracyclines. 2. Regiospecific annulative quinone synthesis. J. Org. Chem. 1980, 45, 2620-2625.
22. 2 (POPd) as a catalyst for the optimized Suzuki-Miyaura cross-coupling of less reactive heteroaryl chlorides and arylboronic acids. Tetrahedron Lett. 2004, 45, 5283-5286.
23. Liu, H.; Huang, X.; Shen, J.; Luo, X.; Li, M.; Xiong, B.; Chen, G.; Shen, J.; Yang, Y.; Jiang, H.; Chen, K. Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses. J. Med. Chem. 2002, 45, 4816-4827.
24. Soliva, R.; Almansa, C.; Kalko, S. G.; Luque, F. J.; Orozco, M. Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site. J. Med. Chem. 2003, 46, 1372-1382.
25. Young, J. M.; Panah, S.; Satchawatcharaphong, C.; Cheung, P. S. Human whole blood assays for inhibition of prostaglandin G/H synthase-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane 62 production. Inflammation Res. 1996, 45, 246-253.